Magaldrate
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a682683 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code |
A02AD02 (WHO) A02AF01 (WHO) (combination with antiflatulents) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Negligible |
Metabolism | Nil |
Excretion | Fecal and renal |
Identifiers | |
| |
CAS Number | 1317-26-6 |
PubChem (CID) | 6336542 |
ChemSpider | 4891688 |
UNII | 6V88E24N5T |
Chemical and physical data | |
Formula | AlMg2(OH)7·H2O |
Molar mass | 212.66 g/mol |
| |
(verify) |
Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.
Available forms
Magaldrate is available in the form of oral suspension or tablets.
Pharmacology
Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly in gastric acid to Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[1]
Interactions and adverse reactions
Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
References
- ↑ Laurence L., Brunton. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.
This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.